Clinical efficacy of low-dose ticagrelor on patients with coronary heart disease after 6 months of PCI

Abstract

Objective To investigate the clinical effect of low dose ticagrelor on patients with coronary heart disease after 6 months of PCI. Methods Fifty-two patients with review at 6 months after PCI were selected. The patients were divided into observation group (ticagrelor group) and control group (clopidogrel group), with 26 patients in each group according to the type of adenosine diphosphate globin antagonist. The patients in the observation group were treated with ticagrelor (90 mg) postoperatively, and low-dose ticagrelor (45 mg) after 6 months. The patients in the control group were treated with clopidogrel (75 mg), both groups were treated with aspirin. The patients were given continuous observation for 3 months, after 6 months of PCI and after 3 months of drugs administration, the thromboelastography results, the adverse events and inflammatory cytokines were compared between the two groups. Results After taking medicine for 3 months, the platelet aggregation induced by Arachidonic acid (AA) in observation group [(68.24±17.63) %]was higher than that in control group [(47.91±15.97)%], the platelet aggregation induced by adenosine diphosphate (ADP) was higher [(71.48±12.78)%] than that of the control group [(59.63±14.26)%], the maximum blood clot formation (MAADP) of ADP-activated platelets in observation group [(31.76±6.88)mm] was lower than that in control group [(46.28±10.91)mm], there were significant differences(P<0.05). The number of major cardiac event (MACE) and drug-related adverse events in the observation group was 4 cases(15.38%), which was lower than that in the control group [8 cases(30.77%)], there were significant differences(P<0.05). The levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were lower in the observation group than those in the control group(P<0.05). Conclusions The anti-platelet aggregation of low-dose ticagrelor in patients with coronary heart disease at 6 months after PCI is high, which can reduce the incidence of adverse events and is worth popularizing in clinical practice. Key words: Coronary heart disease; Percutaneous coronary intervention; Low dose; Ticagrelor